Ionis Pharmaceuticals (IONS) Stock Statistics & Valuation Metrics

Ionis Pharmaceuticals has a market cap or net worth of $5.61B. The enterprise value is $4.72B.

Ionis Pharmaceuticals has 159,159,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ionis Pharmaceuticals’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -17.40%.

The current PE Ratio of Ionis Pharmaceuticals is -11.52. Ionis Pharmaceuticals’s PEG ratio is -0.02.

In the last 12 months, Ionis Pharmaceuticals had revenue of 705.14M and earned -453.90M in profits. Earnings per share was -3.04.

In the last 12 months, operating cash flow was -501.78M and capital expenditures -67.39M, giving a free cash flow of -569.17M billion.

Ionis Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Ionis Pharmaceuticals upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.

Ionis Pharmaceuticals as a current ratio of 8.47, with Debt / Equity ratio of 234.73%

In the past 12 months, Ionis Pharmaceuticals has paid -6.17M in taxes.

Ionis Pharmaceuticals EV to EBITDA ratio is -13.47, with an EV/FCF ratio of -11.72.

Ionis Pharmaceuticals has $2.15B in cash and marketable securities with $1.41B in debt, giving a net cash position of -$735.04M billion.

Gross margin is 97.61%, with operating margin of -67.37%, and net profit margin of -64.37%.

The average price target for Ionis Pharmaceuticals is $56.06, which is 11.43% higher than the current price. The consensus rating is Moderate Buy